10-Q: Sonoma Pharmaceuticals Reports Q2 2025 Results with Revenue Growth and Ongoing Losses

Sonoma Pharmaceuticals experienced revenue growth in the second quarter of fiscal year 2025, but continues to operate at a loss, with ongoing efforts to improve financial controls.

Summary

• Sonoma Pharmaceuticals reported a net loss of $610,000 for the three months ended September 30, 2024, and a net loss of $1,753,000 for the six months ended September 30, 2024.
• The company's revenue increased to $3.579 million for the three months ended September 30, 2024, compared to $2.731 million for the same period in 2023.
• For the six months ended September 30, 2024, revenue was $6.970 million, up from $6.158 million in the prior year.
• The company's accumulated deficit was $196.102 million as of September 30, 2024.
• Cash and cash equivalents totaled $4.078 million as of September 30, 2024, compared to $3.128 million as of March 31, 2024.
• The company had working capital of $8.912 million as of September 30, 2024.
• The company sold 539,744 shares of common stock for net proceeds of $2.289 million between May 13, 2024 and September 18, 2024.
• A reverse stock split of 1-for-20 was implemented on August 29, 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with positive revenue growth offset by ongoing losses, internal control issues, and going concern risks. The sentiment is cautiously negative due to the financial challenges and control weaknesses.

Positives

• The company experienced significant revenue growth in both the three and six month periods ending September 30, 2024.
• Gross profit increased due to higher revenue and improved product mix.
• The company successfully raised capital through the sale of common stock.
• The company's cash position improved compared to the end of the previous fiscal year.
• The company's working capital increased compared to the end of the previous fiscal year.

Negatives

• The company continues to operate at a net loss.
• The company has a significant accumulated deficit.
• The company's disclosure controls and procedures were deemed ineffective due to material weaknesses in internal controls over financial reporting.
• The company relies on a few key customers for a significant portion of its revenue.
• The company is exposed to risks from foreign currency devaluation.

Risks

• The company's ability to continue as a going concern is uncertain due to its history of losses.
• The company may not be able to secure additional capital on commercially acceptable terms.
• The company's financial results could be impacted by a potential recession in the United States.
• The company faces a substantial Mexico tax liability, intercompany debt, unpaid technical assistance charges and accrued interest due in 2027.
• The company's internal controls over financial reporting are not effective.

Future Outlook

Management believes that the Company has access to additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means; however, the Company cannot provide any assurance that other new financings will be available on commercially acceptable terms, if needed.

Management Comments

• Management believes that the Company has access to additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means.
• Management is actively engaged in remediation efforts to address the material weaknesses identified in the managements evaluation of internal controls and procedures.

Industry Context

The company operates in the healthcare sector, specifically in wound care, dermatology, and animal health, which are competitive markets with established players. The company's focus on hypochlorous acid (HOCl) products provides a unique selling proposition, but it must continue to innovate and expand its market reach to compete effectively.

Comparison to Industry Standards

• Sonoma Pharmaceuticals' revenue growth of 31% for the three months ended September 30, 2024, is a positive sign, but it is important to compare this to the growth rates of similar companies in the medical device and healthcare sectors.
• Companies like Integra LifeSciences and Smith & Nephew, which are involved in wound care, have reported varying growth rates, and Sonoma's performance should be benchmarked against these.
• The company's net loss and accumulated deficit are concerning and need to be addressed through cost management and revenue growth strategies.
• The company's internal control weaknesses are a significant issue that needs to be resolved to meet industry standards for financial reporting.

Management Changes

Corporate Governance

Legal Proceedings

• The company may be involved in legal matters arising in the ordinary course of business, including matters involving proprietary technology, but management believes that such matters are currently insignificant.

Stakeholder Impact

• Shareholders are impacted by the company's ongoing losses and the need for additional capital.
• Employees are impacted by the company's efforts to improve internal controls and manage costs.
• Customers and suppliers are impacted by the company's ability to maintain its operations and deliver products.
• Creditors are impacted by the company's financial condition and its ability to meet its obligations.

Next Steps

• The company needs to continue to focus on revenue growth and cost management.
• The company must remediate the material weaknesses in its internal controls over financial reporting.
• The company needs to explore options for securing additional capital.
• The company should continue to monitor and manage its foreign currency exposure.
• The company should continue to monitor and manage its tax liability in Mexico.

Key Dates

Keywords

hypochlorous acid, wound care, dermatology, revenue, net loss, financial results, stock split, internal controls, capital raise, medical devices